[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557559":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":41,"responsibleParty":185,"collaborators":25,"id":187,"slug":188,"hasResults":189,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":189,"sex":195,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":25,"studyType":201,"phases":202,"briefSummary":204,"conditions":205,"keywords":209,"overallStatus":96,"whyStopped":25,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},{"fullName":5,"class":6},"FrontAce Scientific Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sperstent® peripheral spot stent system","EXPERIMENTAL","subjects using the Sperstent® peripheral spot stent system",[13],"Device: Sperstent® peripheral spot stent system",{"label":15,"type":16,"description":17,"interventionNames":18},"Everflex® self-expanding peripheral stent system","ACTIVE_COMPARATOR","subjects using the Everflex® self-expanding peripheral stent system",[19],"Device: Everflex® self-expanding peripheral stent system",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Sperstent® peripheral spot stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Everflex® self-expanding peripheral stent system, Percutaneous Transluminal Angioplasty (PTA), Digital Subtraction Angiography（DSA）",[15],[30,36],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Min Zhou, Dr.","CONTACT","01186-25-83106666","60770","zhouminnju@126.com",{"name":37,"role":32,"phone":38,"phoneExt":39,"email":40},"Xiang Wang, Dr.","01186-21-38804518","22265","vascular_doc@qq.com",[42,58,70,82,94,107,119,130,142,154,166,177],{"facility":43,"status":44,"city":45,"state":46,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Beijing Friendship Hospital, Capital Medical University","NOT_YET_RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":32,"phone":25,"phoneExt":25,"email":25},"Hai Feng",{"facility":59,"status":44,"city":60,"state":61,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"The First Affiliated Hospital of Chongqing Medical University","Chongqing","Chongqing Municipality",{"type":50,"coordinates":63},[64,65],106.55771,29.56026,{"lat":65,"lon":64},[68],{"name":69,"role":32,"phone":25,"phoneExt":25,"email":25},"Yu Zhao",{"facility":71,"status":44,"city":72,"state":73,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"The Second Hospital of Hebei Medical University","Shijiazhuang","Hebei",{"type":50,"coordinates":75},[76,77],114.47861,38.04139,{"lat":77,"lon":76},[80],{"name":81,"role":32,"phone":25,"phoneExt":25,"email":25},"Wei Bi",{"facility":83,"status":44,"city":84,"state":85,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan",{"type":50,"coordinates":87},[88,89],113.64861,34.75778,{"lat":89,"lon":88},[92],{"name":93,"role":32,"phone":25,"phoneExt":25,"email":25},"Zhen Li",{"facility":95,"status":96,"city":97,"state":98,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology","RECRUITING","Wuhan","Hubei",{"type":50,"coordinates":100},[101,102],114.26667,30.58333,{"lat":102,"lon":101},[105],{"name":106,"role":32,"phone":25,"phoneExt":25,"email":25},"Zibo Feng",{"facility":108,"status":96,"city":109,"state":110,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Nanjing Drum Tower Hospital","Nanjing","Jiangsu",{"type":50,"coordinates":112},[113,114],118.77778,32.06167,{"lat":114,"lon":113},[117],{"name":118,"role":32,"phone":25,"phoneExt":25,"email":25},"Min Zhou",{"facility":120,"status":44,"city":121,"state":110,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Affiliated Hospital of Nantong University","Nantong",{"type":50,"coordinates":123},[124,125],120.87472,32.03028,{"lat":125,"lon":124},[128],{"name":129,"role":32,"phone":25,"phoneExt":25,"email":25},"Hui Zhao",{"facility":131,"status":44,"city":132,"state":133,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Renji Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality",{"type":50,"coordinates":135},[136,137],121.45806,31.22222,{"lat":137,"lon":136},[140],{"name":141,"role":32,"phone":25,"phoneExt":25,"email":25},"Meng Ye",{"facility":143,"status":44,"city":144,"state":145,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"The Affiliated Hospital of Southwest Medical University","Luzhou","Sichuan",{"type":50,"coordinates":147},[148,149],105.42575,28.8903,{"lat":149,"lon":148},[152],{"name":153,"role":32,"phone":25,"phoneExt":25,"email":25},"Yong Liu",{"facility":155,"status":44,"city":156,"state":157,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":50,"coordinates":159},[160,161],120.16142,30.29365,{"lat":161,"lon":160},[164],{"name":165,"role":32,"phone":25,"phoneExt":25,"email":25},"Hongkun Zhang",{"facility":167,"status":44,"city":168,"state":25,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Hospital of Chengdu University of TCM","Chengdu",{"type":50,"coordinates":170},[171,172],104.06667,30.66667,{"lat":172,"lon":171},[175],{"name":176,"role":32,"phone":25,"phoneExt":25,"email":25},"Chunshui He",{"facility":178,"status":96,"city":132,"state":25,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"Shanghai East Hospital",{"type":50,"coordinates":180},[136,137],{"lat":137,"lon":136},[183],{"name":184,"role":32,"phone":25,"phoneExt":25,"email":25},"Xiang Wang",{"type":186,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100557559","a-trail-of-sperstent-used-for-residual-lesions-of-femoropopliteal-arteries-100557559",false,"NCT06539689","A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries","A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries","SURF","Inclusion Criteria:\n\n* Age 18-85 years old, male or female;\n* The target lesion is located in the superficial femoral artery or the proximal popliteal artery;\n* Peripheral arterial stenosis or occlusive disease with symptoms consistent with the Rutherford classification 2 to 5;\n* Estimated life expectancy \\>1 year;\n* Subject has been informed of and understands the nature of the study and provides signed informed consent to participate in the study.\n\nAngiographic Inclusion Criteria:\n\n* Stenosis rate ≥70% under DSA by visual estimate, or 100% occluded lesion with a total lesion length less than 150mm (by visual estimate);\n* Reference vessel diameter is between 3 mm and 7.5 mm, 50mm≤Total cumulative length of target lesions≤250mm; (In the case of bilimb lesions, a single target lesion with one limb meeting the protocol criteria is selected by the investigator; More than 2cm between lesions are considered as 2 lesions);\n* After PTA treatment by DCB, there exists residual lesions, such as the target lesion has over 30% residual DS and\u002For presence of at least one post-PTA dissection (Type A-F) (by visual estimate);\n* Patients with unobstructed inflow tract or successfully treated, visual residual stenosis ≤50%;\n* Angiography showed at least one outflow tract was unobstructed at the distal end (Stenosis degree ≤70% before intervention).\n\nExclusion Criteria:\n\n* Target vessel had undergone open surgery such as bypass surgery or the target lesion is in-stent restenosis;\n* Patients with serum creatinine \\>2.5mg\u002Fdl during screening or undergoing long-term hemodialysis or peritoneal dialysis;\n* Severe coagulation disorder;\n* Patients with major vascular-related diseases, including acute lower extremity ischemia, active disseminated intravascular coagulation, thromboangiitis obliterans, deep vein thrombosis, and aneurysms of therapeutic lateral vessels (deep femur, superficial femur, or popliteal artery);\n* A history of major organ failure or other serious illness (including severe coronary heart disease, severe cardiac insufficiency, severe neurosis, or mental illness); Have received or plan organ transplantation, severe gastrointestinal bleeding);\n* Myocardial infarction or symptomatic stroke occurred within 3 months prior to enrollment;\n* Thrombolysis of target vessel within 72 hours before surgery, did not completely dissolve the thrombus;\n* Systemic infection or uncontrolled infection within the target limb;\n* Known allergy to contrast agents, nickel or titanium (Nitinol), heparin, aspirin, clopidogrel, anesthetics;\n* Women who are pregnant or breast-feeding, or women of childbearing age who have family plans within 1 year;\n* Patients who are planning to have major lower limb amputations on the target side of the lesion;\n* Endovascular or surgical procedures are performed on the target limb within 30 days before or 30 days after surgery;\n* Participating in clinical trials of other medical devices or drugs;\n* The investigator considers the patient is not suitable for participation in the clinical trial.\n\nAngiographic Exclusion Criteria:\n\n* Failure of the guidewire to pass through the lesion；\n* During the procedure, the target lesions had received or were scheduled to receive volume reduction procedures such as cryogenic angioplasty, laser angioplasty, and percutaneous intracavity plaque gyrotomy；\n* The target lesion before stent implantation is thrombotic obliteration, which is not suitable for stent implantation；\n* The target lesions were severely calcified and could not fully predilate; Or grade 4 calcification；\n* Acute vascular occlusion or acute or subacute thrombosis in the target lesion；\n* Stent was implanted into the target vessel before enrollment.","ALL","18 Years","85 Years",{"count":199,"type":200},240,"ESTIMATED","INTERVENTIONAL",[203],"NA","This is a prospective, multi-center, randomized trial designed to investigate the efficacy and safety of Sperstent® peripheral spot stent system versus Everflex® self-expanding peripheral stent system in the endovascular treatment of post-balloon angioplasty (post-PTA) residual lesions including stenoses and\u002For dissections in femoral and proximal popliteal arteries.",[206,207,208],"Peripheral Arterial Disease","Stenosis","Dissection",[206,210],"Spot stent","2024-08-01",{"date":213,"type":214},"2024-08-06","ACTUAL",{"date":216,"type":214},"2024-06-04",{"date":218,"type":200},"2026-12-31",{"name":5,"class":6},12]